

US Patent Notice of Allowance

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to report to shareholders an update on the patent application “Treatment of Bone Marrow Pathologies with Polysulfated Polysaccharides” (US application number 16/636,545).

Paradigm has received notification from the US Patent and Trademark Office (**USPTO**) that the patent application has been examined and received a Notice of Allowance in the US. The USPTO issues a Notice of Allowance after an examiner determines that a patent application satisfies the requirements for patentability.

A summary of the first claim of the accepted patent (16/636,545) refers to a method for improving knee function in a human having bone marrow edema lesions as assessed by magnetic resonance imaging (**MRI**) and osteoarthritis in a knee, the method including the treatment of the knee with administering an amount of pentosan polysulfate.

Paradigm Managing Director, Mr Paul Rennie, commented: *“This is an excellent outcome for Paradigm as we continue to build on the strength of our IP portfolio across all our indications. We are focussed on continuing to add additional layers of protection as data becomes available from our preclinical and clinical programs. The Paradigm team continues to further build patent protection around iPPS, a potential blockbuster therapeutic for osteoarthritis. The company looks forward to further updating shareholders on additions to our IP portfolio”.*

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (**iPPS**) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd.

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com